558 related articles for article (PubMed ID: 26734993)
1. Circulating microRNA-based screening tool for breast cancer.
Frères P; Wenric S; Boukerroucha M; Fasquelle C; Thiry J; Bovy N; Struman I; Geurts P; Collignon J; Schroeder H; Kridelka F; Lifrange E; Jossa V; Bours V; Josse C; Jerusalem G
Oncotarget; 2016 Feb; 7(5):5416-28. PubMed ID: 26734993
[TBL] [Abstract][Full Text] [Related]
2. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
Duchnowska R; Jassem J; Goswami CP; Dundar M; Gökmen-Polar Y; Li L; Woditschka S; Biernat W; Sosińska-Mielcarek K; Czartoryska-Arłukowicz B; Radecka B; Tomasevic Z; Stępniak P; Wojdan K; Sledge GW; Steeg PS; Badve S
J Neurooncol; 2015 Mar; 122(1):205-16. PubMed ID: 25559688
[TBL] [Abstract][Full Text] [Related]
3. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
4. Circulating miR-195 as a Therapeutic Biomarker in Turkish Breast Cancer Patients.
Cecene G; Ak S; Eskiler GG; Demirdogen E; Erturk E; Gokgoz S; Polatkan V; Egeli U; Tunca B; Tezcan G; Topal U; Tolunay S; Tasdelen I
Asian Pac J Cancer Prev; 2016; 17(9):4241-4246. PubMed ID: 27797225
[TBL] [Abstract][Full Text] [Related]
5. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA.
Yie SM; Luo B; Ye NY; Xie K; Ye SR
Clin Exp Metastasis; 2006; 23(5-6):279-89. PubMed ID: 17086357
[TBL] [Abstract][Full Text] [Related]
6. Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer.
Shao B; Wang X; Zhang L; Li D; Liu X; Song G; Cao H; Zhu J; Li H
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828709. PubMed ID: 30786836
[TBL] [Abstract][Full Text] [Related]
7. Circulating microRNAs in plasma as early detection markers for breast cancer.
Cuk K; Zucknick M; Heil J; Madhavan D; Schott S; Turchinovich A; Arlt D; Rath M; Sohn C; Benner A; Junkermann H; Schneeweiss A; Burwinkel B
Int J Cancer; 2013 Apr; 132(7):1602-12. PubMed ID: 22927033
[TBL] [Abstract][Full Text] [Related]
8. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients.
Silva J; García V; García JM; Peña C; Domínguez G; Díaz R; Lorenzo Y; Hurtado A; Sánchez A; Bonilla F
Breast Cancer Res; 2007; 9(4):R55. PubMed ID: 17711569
[TBL] [Abstract][Full Text] [Related]
9. MiR-4728-3p could act as a marker of HER2 status.
Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
[TBL] [Abstract][Full Text] [Related]
10. A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer.
Zhang L; Xu Y; Jin X; Wang Z; Wu Y; Zhao D; Chen G; Li D; Wang X; Cao H; Xie Y; Liang Z
Breast Cancer Res Treat; 2015 Nov; 154(2):423-34. PubMed ID: 26476723
[TBL] [Abstract][Full Text] [Related]
11. Tumor-suppressive microRNA-34a inhibits breast cancer cell migration and invasion via targeting oncogenic TPD52.
Li G; Yao L; Zhang J; Li X; Dang S; Zeng K; Zhou Y; Gao F
Tumour Biol; 2016 Jun; 37(6):7481-91. PubMed ID: 26678891
[TBL] [Abstract][Full Text] [Related]
12. Detection of circulating tumor cells in breast cancer patients using multiplex reverse transcription-polymerase chain reaction and specific primers for MGB, PTHRP and KRT19 correlation with clinicopathological features.
Skondra M; Gkioka E; Kostakis ID; Pissimissis N; Lembessis P; Pectasides D; Koutsilieris M
Anticancer Res; 2014 Nov; 34(11):6691-9. PubMed ID: 25368276
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of miR-21, miR-125b and miR-191 in breast cancer tissue.
Mar-Aguilar F; Luna-Aguirre CM; Moreno-Rocha JC; Araiza-Chávez J; Trevino V; Rodríguez-Padilla C; Reséndez-Pérez D
Asia Pac J Clin Oncol; 2013 Mar; 9(1):53-9. PubMed ID: 22898264
[TBL] [Abstract][Full Text] [Related]
14. The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion.
Petrović N; Mandušić V; Stanojević B; Lukić S; Todorović L; Roganović J; Dimitrijević B
Med Oncol; 2014 Mar; 31(3):867. PubMed ID: 24488617
[TBL] [Abstract][Full Text] [Related]
15. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological significance of β -tubulin isotype III gene expression in breast cancer patients.
He Q; Peng B; Zhuang D; Xiao L; Zheng L; Fan Z; Zhu J; Xu B; Xu C; Zhao J; Wu L; Zhou P; Hou L; Yu F; Zhao G
Cancer Biomark; 2015; 15(6):823-31. PubMed ID: 26406408
[TBL] [Abstract][Full Text] [Related]
17. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.
Mook S; Knauer M; Bueno-de-Mesquita JM; Retel VP; Wesseling J; Linn SC; Van't Veer LJ; Rutgers EJ
Ann Surg Oncol; 2010 May; 17(5):1406-13. PubMed ID: 20094918
[TBL] [Abstract][Full Text] [Related]
18. Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.
Karsten M; Stempel M; Radosa J; Patil S; King TA
Ann Surg Oncol; 2016 Feb; 23(2):471-6. PubMed ID: 26340863
[TBL] [Abstract][Full Text] [Related]
19. Plasma Circulating Cell-free Nuclear and Mitochondrial DNA as Potential Biomarkers in the Peripheral Blood of Breast Cancer Patients.
Mahmoud EH; Fawzy A; Ahmad OK; Ali AM
Asian Pac J Cancer Prev; 2015; 16(18):8299-305. PubMed ID: 26745076
[TBL] [Abstract][Full Text] [Related]
20. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
